ALNEO Trial: Neoadjuvant Alectinib in Resectable Stage III ALK+ NSCLC – WCLC 2024 Interim Data.

32 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Watch the latest update from the ALNEO-GOIRC-01-2020 phase II trial (MA01.03), presented at WCLC 2024, evaluating neoadjuvant alectinib in patients with potentially resectable stage III ALK-positive non-small-cell lung cancer (NSCLC). This interim analysis highlights the promise of targeted therapy in the neoadjuvant setting for oncogene-driven tumors.

???? Stay informed on precision oncology and evolving neoadjuvant therapies in lung cancer.

#ALNEOTrial #ALKPositiveNSCLC #Alectinib #WCLC2024 #LungCancer #TargetedTherapy #NSCLC
Categoria
Oncology
Commenta per primo questo video.

Prossimo